Top Markets
Coin of the day
Kinnate Biopharma Inc. Kinnate Biopharma Inc.

Kinnate Biopharma Inc.

KNTE
Rangering i aksjer #21072
Kinnate Biopharma Inc. is a U.S.-based biopharmaceutical company primarily... Kinnate Biopharma Inc. is a U.S.-based biopharmaceutical company primarily focused on identifying and advancing small-molecule drugs that target kinase enzymes to treat cancers defined by specific genetic markers. The company's product pipeline includes: KIN-2787: An inhibitor of rapidly accelerated fibrosarcoma (RAF), currently being developed to treat patients with lung cancer, melanoma, and other forms of solid tumors. KIN-3248: A small-molecule kinase inhibitor designed to counteract cancer-associated genetic mutations in the fibroblast growth factor receptors, specifically FGFR2 and FGFR3. KIN004 Program: This program encompasses early-stage small-molecule research, including a Cyclin-Dependent Kinase 12 (CDK12) inhibitor. Established in 2018, Kinnate Biopharma Inc. maintains its headquarters in San Francisco, California. It was formerly a division of Fount Therapeutics, LLC.
Aksjekurs
$2.65
Sist synkronisert: 2024-04-03
Markedsverdi
$115.71M
Endring (1 dag)
0.00%
Endring (1 år)
0.00%
Land
US
Handel Kinnate Biopharma Inc. (KNTE)

Kategori

Historikk for aksjesplitt for Kinnate Biopharma Inc. (KNTE)
Aksjen Kinnate Biopharma Inc. (symbol: KNTE) har gjennomgått totalt 0 aksjesplitt.
Den nyeste splittelsen skjedde Aug 23, 2026.
Én KNTE-aksje kjøpt før Aug 23, 2026 tilsvarer i dag 0 KNTE-aksjer.
Liste over aksjesplitt
År Splitt Multiplikator Kumulativ multiplikator
Ikke nok data for de angitte datoene.
Aksjesplitt for lignende selskaper eller konkurrenter
Selskap Antall aksjesplitt Kumulativ multiplikator Land
1 x2
US
0 -
NL
0 -
US
1 x3
AU
0 -
CH